Research map: A patent perspective of RSK inhibitors to treat cancer (2020-present)

Back to the article

Papers in this map

  1. UCSF ChimeraX: Meeting modern challenges in visualization and analysis · Thomas D. Goddard · 2017 · 6057 citations · Cited by this paper
  2. Sirtuin modulators: a review of patents from 2020 to 2024 · 2025 · Related
  3. Choosing the right cell line for breast cancer research · Deborah L. Holliday · 2011 · 1576 citations · Cited by this paper
  4. A patent review of Mpro protease inhibitors for the treatment of COVID-19 infections (2020 – present) · 2025 · Related
  5. Negative feedback regulation of the ERK1/2 MAPK pathway · David A. Lake · 2016 · 593 citations · Cited by this paper
  6. Therapeutic applications of benzoxaborole compounds: a patent and literature analysis (2019–2024) · 2025 · Related
  7. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials · Stephen A. Harrison · 2020 · 495 citations · Cited by this paper
  8. An updated patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2020–2025) · 2026 · Related
  9. (S)-13-[(Dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno- 1H,13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and Related Analogues: Isozyme Selective Inhibitors of Protein Kinase Cβ · Michael R. Jirousek · 1996 · 340 citations · Cited by this paper
  10. 5’-Ectonucleotidase (CD73) inhibitors: a patent review (2021-present) · 2026 · Related
  11. BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo · Gopal P. Sapkota · 2006 · 311 citations · Cited by this paper
  12. PCSK9 inhibitors: an updated patent review 2024–2025 · 2026 · Related
  13. Identification of the First Specific Inhibitor of p90 Ribosomal S6 Kinase (RSK) Reveals an Unexpected Role for RSK in Cancer Cell Proliferation · Jeffrey Allen Smith · 2005 · 286 citations · Cited by this paper
  14. Topoisomerase II inhibitors in oncology: an updated patent review (2016-present) · 2025 · Related
  15. RSK Is a Principal Effector of the RAS-ERK Pathway for Eliciting a Coordinate Promotile/Invasive Gene Program and Phenotype in Epithelial Cells · Ulrik Doehn · 2009 · 227 citations · Cited by this paper
  16. Recent advances in the discovery of PKMYT1-targeting drugs: a patent review (2021–2025) · 2026 · Related
  17. The Serine/Threonine Protein Kinase, p90 Ribosomal S6 Kinase, Is an Important Regulator of Prostate Cancer Cell Proliferation · David E. Clark · 2005 · 202 citations · Cited by this paper
  18. Implementation and outcomes of China’s drug patent linkage system: lessons from international experience · 2025 · Related
  19. Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors · Likun Wang · 2012 · 199 citations · Cited by this paper
  20. An updated patent review of acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease (2021–present) · 2025 · Related
  21. Functional Characterization of Human RSK4, a New 90-kDa Ribosomal S6 Kinase, Reveals Constitutive Activation in Most Cell Types · Bettina A. Dummler · 2005 · 125 citations · Cited by this paper
  22. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells · Ning Ji · 2018 · 111 citations · Cited by this paper
  23. The Role of Small Molecules Containing Fluorine Atoms in Medicine and Imaging Applications · Emily Henary · 2024 · 106 citations · Cited by this paper
  24. An siRNA screen identifies RSK1 as a key modulator of lung cancer metastasis · Romain Lara · 2011 · 94 citations · Cited by this paper
  25. Rsk2 allosterically activates estrogen receptor α by docking to the hormone‐binding domain · David E. Clark · 2001 · 82 citations · Cited by this paper
  26. Overcoming resistance to sonic hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastoma · Mary Rose Pambid · 2013 · 72 citations · Cited by this paper
  27. Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer · Katarzyna Anna Ludwik · 2016 · 64 citations · Cited by this paper
  28. Design of a Phase 2 Clinical Trial of an ASK1 Inhibitor, GS-4997, in Patients with Diabetic Kidney Disease · Joseph H. Lin · 2014 · 61 citations · Cited by this paper
  29. Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations · Hao Chen · 2022 · 59 citations · Cited by this paper
  30. RSK2 Protein Suppresses Integrin Activation and Fibronectin Matrix Assembly and Promotes Cell Migration · Joanna E. Gawecka · 2012 · 56 citations · Cited by this paper
  31. Insights into the Inhibition of the p90 Ribosomal S6 Kinase (RSK) by the Flavonol Glycoside SL0101 from the 1.5 Å Crystal Structure of the N-Terminal Domain of RSK2 with Bound Inhibitor · Darkhan Utepbergenov · 2012 · 47 citations · Cited by this paper
  32. Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells · Alastair Davies · 2015 · 41 citations · Cited by this paper
  33. Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer · Stelios Chrysostomou · 2021 · 39 citations · Cited by this paper
  34. An oral first‐in‐class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer · Miho Ushijima · 2022 · 38 citations · Cited by this paper
  35. Dynamic control of RSK complexes by phosphoswitch‐based regulation · Gergő Gógl · 2017 · 37 citations · Cited by this paper
  36. Ribosomal S6 kinase 4 (RSK4) expression in ovarian tumors and its regulation by antineoplastic drugs in ovarian cancer cell lines · Fabián Arechavaleta-Velasco · 2016 · 34 citations · Cited by this paper
  37. Improving the Affinity of SL0101 for RSK Using Structure-Based Design · Roman M. Mrozowski · 2012 · 32 citations · Cited by this paper
  38. Structural Diversity of the Active N-Terminal Kinase Domain of p90 Ribosomal S6 Kinase 2 · Margarita L. Malakhova · 2009 · 31 citations · Cited by this paper
  39. Effect of RSK4 on biological characteristics of colorectal cancer · Qingqing Ye · 2018 · 29 citations · Cited by this paper

Source: OpenAlex (CC0)